Last $47.96 USD
Change Today +1.21 / 2.59%
Volume 3.3M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Open
$46.70
Previous Close
$46.75
Day High
$48.01
Day Low
$46.56
52 Week High
03/4/14 - $57.52
52 Week Low
10/31/13 - $36.97
Market Cap
17.9B
Average Volume 10 Days
4.0M
EPS TTM
$2.00
Shares Outstanding
374.0M
EX-Date
07/17/07
P/E TM
23.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Venus Remedies Signs European Meropenem Licensing Deal with Mylan

Venus Remedies has entered into a non-exclusive licensing deal with Mylan for the former's generic meropenem. Under the agreement, Venus Remedies will retain responsibility for manufacturing the antibiotic while Mylan will co-market the product in Denmark, Finland, and Sweden for a period of five years.

Mylan, Inc. Launches Generic Version of Hoffmann-La Roche's Boniva(R) Injection

Mylan Inc. announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva(R) Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of osteoporosis in postmenopausal women.

Mylan Inc. Announces New Drug Application for Three Times Per Week Glatiramer Acetate Injection 40 mg/mL

Mylan Inc. announced that its abbreviated new drug application for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration. This product is the generic version of Teva's Copaxone 40 mg/mL, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and expects to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval. Copaxone 40 mg/mL had U.S. sales of approximately $411.5 million for the 12 months ending June 30, 2014. Currently, Mylan has 294 ANDAs pending FDA approval representing $105.7 billion in annual brand sales. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending Dec. 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $47.96 USD +1.21

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $63.95 USD +0.75
Perrigo Co PLC $145.26 USD +1.58
UCB SA €68.62 EUR +0.72
WW Grainger Inc $248.67 USD +0.25
WESCO International Inc $81.88 USD -0.29
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 31.9x
Price/Sales 2.5x
Price/Book 5.2x
Price/Cash Flow 30.1x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.